Share
5,887 Posts.
lightbulb Created with Sketch. 226
clock Created with Sketch.
17/05/16
08:57
Share
Originally posted by gsad1000
↑
You are 100% correct, doctors may or may not use the ResApp and many initially won't due to the health administration industry being so backward.
But the factor you must consider is the health consumer and doctor google. The power in the doctor-patient relationship is moving toward the patient and has been for a while. Doctor won't use the app but the patient will before seeing the doctor.
Expand
IIRC, the initial customer for RAP will be telehealth companies. But if you mean that consumers will pressure the telehealth companies to adopt it, then I agree.
Originally posted by gedck
↑
And perhaps also another "potential" perspective to consider:
(i) Patient is presumed clear of infection from initial consultation (tele-health or in person) based on other products / existing approaches.
(ii) Condition of the patient deteriorates and they end up in an ER.
(ii) Doctor in the ER then rapidly diagnoses respiratory infection using ResApp and proper and prompt treatment is given (as expanding and implementing ResApp in emergency room settings was one of the many reasons for the recent CR...).
(iv) Medical industry (and consumers) realise (hopefully) the easiness and effectiveness of ResApp as a frontline diagnostic tool, thus avoiding timely, dangerous and avoidable misdiagnosis.
Just another perspective/scenario to consider....
Expand
Yes, if Resapp consistently outperforms other methods, then it will come to dominate the market.
I'm still gasping for the adult results.